CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

1:14-cv-00111

Overview

Case Number 1:14-cv-00111
Filing Date 2014-01-30
Status Terminated
Termination Date 2015-09-14
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Hisamitsu Pharmaceutical Co. Inc. NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Noven Therapeutics LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Noven Pharmaceuticals Inc. Operating Company

Represented By

5 Attorneys Listed

Michael K. Levy

UNDELIVERABLE EMAIL 9/22/2017

Cynthia L Hardman

UNDELIVERABLE EMAIL 4/10/2019

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Plaintiff

LTS Lohmann Therapie-Systeme AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis International Pharmaceutical, LTD Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharma AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

5 Attorneys Listed

Nicholas N. Kallas

Email: nkallas@venable.com

Dominick A. Conde

Email: dconde@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Christopher E. Loh

Email: cloh@venable.com

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 8 proceedings
🏛️
USPTO PTAB Trials 4 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (12 found):
PTAB: 4 U.S. Courts: 8
USPTO PTAB Trial 2014-11-13
IPR2015-00268

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6335031)
Status: Final Written Decision
USPTO PTAB Trial 2014-11-13
IPR2015-00265

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00550

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6335031)
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00549

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2015-11-05
1:15-cv-01025

Novartis Pharmaceuticals Corporation v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2015-11-05
1:15-cv-01026

Novartis Pharmaceuticals Corporation v. Dr. Reddy's Laboratories, Ltd.

Asserted Patent
Status: DED
U.S. District Court 2014-06-19
1:14-cv-00777

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-04-03
1:13-cv-00527

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00370

Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00371

Novartis Pharmaceuticals Corporation v. Actavis Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-09
1:11-cv-01112

Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-03
1:11-cv-01077

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6316023
TTS containing an antioxidant
Filed: 2000-12-20
Issued: 2001-11-13
Expired (Term Ended)
Expires: 2020-12-20
US6335031
TTS containing an antioxidant
Filed: 1999-04-14
Issued: 2002-01-01
Expired (Term Ended)
Expires: 2019-04-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

1

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Procedural / Extension Motion 4 Motion for Summary Judgment (Infringement) 1

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Infringement) Pending / Under Review
[SEALED] Joint Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq., enclosing confidential Stipulation and Noven's Request for Leave to File ...
Entry #46 • 2014-10-20 Document →
Procedural / Extension Motion Pending / Under Review
NOTICE of Withdrawal of Request for Leave to File Summary Judgment by Noven Pharmaceuticals Inc. re (134 in 1:13-cv-00527-RGA, 44 in 1:14-cv-00111-RGA) Letter (...
Entry #48 • 2014-10-22 Document →
Procedural / Extension Motion Pending / Under Review
[SEALED] Letter to The Honorable Richard G. Andrews from John C. Phillips, Jr. regarding Request for Leave to File a Summary Judgment Motion. (Attachments: # 1 ...
Entry #44 • 2014-10-15 Document →
Procedural / Extension Motion Pending
SO ORDERED, re (128 in 1:13-cv-00527-RGA, 37 in 1:14-cv-00111-RGA) Joint STIPULATION TO EXTEND TIME for Expert Discovery and Reply Expert Reports to Various dat...
Entry #— • 2014-07-07
Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME for Expert Discovery and Reply Expert Reports to Various - filed by Noven Pharmaceuticals Inc.. (Phillips, John) (Entered: 07/0...
Entry #37 • 2014-07-03 Document →

Docket Entries

(116 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed against Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Noven Therapeutics LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1451072.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma AG, Novartis International Pharmaceutical, LTD, LTS Lohmann Therapie-Systeme AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(rwc) (Entered: 01/30/2014)

Entry #1 • 2014-01-30
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 01/30/2014)

Entry #2 • 2014-01-30
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/18/13. Date of Expiration of Patent: 1/8/19.Thirty Month Stay Deadline: 6/18/2016. (rwc) (Entered: 01/30/2014)

Entry #3 • 2014-01-30
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,316,023; 6,335,031. (rwc) (Entered: 01/30/2014)

Entry #4 • 2014-01-30
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (rwc) (Entered: 01/30/2014)

Entry #5 • 2014-01-30
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc